Pay in 4 interest-free payments of $5.76 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
Mild nausea or a temporary drop in blood pressure
Xu M, Tan J, Zhu L, Ge C, Zhang Y, Gao F, et al
Several important considerations apply: Individuals with active or severe gastrointestinal disease may experience worsening symptoms due to the gastrointestinal side effects of GLP-1 medications The slowed gastric emptying caused by these drugs could theoretically exacerbate symptoms in people with strictures or obstructive complications of Crohn's disease Weight loss associated with GLP-1 therapy may be inappropriate in patients with Crohn's disease who are already experiencing malnutrition or unintentional weight loss The interaction between GLP-1 medications and the inflammatory processes in IBD is not fully understood Clinical decision-making should involve a thorough assessment of disease activity, nutritional status, presence of complications (such as strictures or fistulas), and the primary indication for GLP-1 therapy
Liraglutide (Saxenda, Victoza) Saxenda is a daily injection that works as a GLP-1 receptor agonist
But experts say any weight loss can result in facial changes
